PTH and hypoparathyroidism: Hypoparathyroidism was the only classic endocrine deficiency disease not treated with the missing hormone until approval of recombinant human parathyroid hormone (1-84) (rhPTH(1-84)) by the United States Food and Drug Administration in 2015 and the European Medicines Agency in 2017.